MARCONI, Peggy Carla Raffaella
 Distribuzione geografica
Continente #
NA - Nord America 10.011
AS - Asia 4.448
EU - Europa 2.976
SA - Sud America 772
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 18.295
Nazione #
US - Stati Uniti d'America 9.834
SG - Singapore 1.831
CN - Cina 1.246
BR - Brasile 635
IT - Italia 614
UA - Ucraina 531
HK - Hong Kong 455
GB - Regno Unito 418
DE - Germania 407
PL - Polonia 344
TR - Turchia 312
VN - Vietnam 275
FI - Finlandia 163
RU - Federazione Russa 136
SE - Svezia 91
MX - Messico 84
CA - Canada 76
FR - Francia 67
ID - Indonesia 67
AR - Argentina 63
NL - Olanda 57
IN - India 56
ZA - Sudafrica 43
JP - Giappone 42
BD - Bangladesh 38
ES - Italia 32
BE - Belgio 29
IQ - Iraq 26
AT - Austria 24
PK - Pakistan 22
EC - Ecuador 21
LT - Lituania 21
UZ - Uzbekistan 19
CZ - Repubblica Ceca 13
MA - Marocco 13
CO - Colombia 11
CL - Cile 10
PY - Paraguay 10
UY - Uruguay 8
VE - Venezuela 8
IE - Irlanda 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
IL - Israele 6
IR - Iran 6
KE - Kenya 5
NP - Nepal 5
SA - Arabia Saudita 5
JM - Giamaica 4
JO - Giordania 4
KR - Corea 4
AZ - Azerbaigian 3
BO - Bolivia 3
DZ - Algeria 3
KZ - Kazakistan 3
MZ - Mozambico 3
OM - Oman 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
CR - Costa Rica 2
EG - Egitto 2
ET - Etiopia 2
EU - Europa 2
GD - Grenada 2
GH - Ghana 2
KG - Kirghizistan 2
LB - Libano 2
MY - Malesia 2
NG - Nigeria 2
NO - Norvegia 2
PE - Perù 2
PH - Filippine 2
RO - Romania 2
SN - Senegal 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
CG - Congo 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
FO - Isole Faroe 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MD - Moldavia 1
MN - Mongolia 1
NI - Nicaragua 1
PT - Portogallo 1
RS - Serbia 1
SR - Suriname 1
SY - Repubblica araba siriana 1
Totale 18.291
Città #
Singapore 1.095
Ashburn 1.054
Fairfield 1.048
Woodbridge 1.031
Houston 609
Jacksonville 553
Chandler 491
Santa Clara 466
Hong Kong 453
Beijing 433
Ann Arbor 427
Seattle 418
Wilmington 361
Cambridge 337
Warsaw 333
New York 303
Ferrara 204
Izmir 186
Dallas 180
Los Angeles 163
Nanjing 148
Princeton 134
San Diego 108
Munich 102
Ho Chi Minh City 95
São Paulo 73
Hanoi 65
Shanghai 65
Jakarta 56
Mexico City 56
Boardman 53
Milan 53
Shenyang 52
Tianjin 49
Buffalo 46
Bologna 44
Chicago 41
Brooklyn 38
Hebei 37
London 37
Hefei 35
Turku 35
The Dalles 34
Jiaxing 33
Tokyo 33
Nanchang 32
Poplar 32
Brussels 29
Montreal 29
Moscow 27
Changsha 26
Stockholm 26
San Jose 25
Chennai 24
Frankfurt am Main 24
Helsinki 23
Orem 23
Atlanta 22
Boston 22
Falls Church 22
Johannesburg 22
Rome 22
Phoenix 21
San Francisco 21
Council Bluffs 20
Denver 20
Norwalk 19
Falkenstein 18
Mountain View 18
Vienna 17
Ningbo 16
Redwood City 16
Rio de Janeiro 16
Toronto 16
Washington 16
San Mateo 15
Dong Ket 14
Jinan 14
Tashkent 14
Zhengzhou 14
Auburn Hills 13
Guangzhou 13
Nuremberg 13
Orange 13
Amsterdam 12
Ankara 12
Brasília 12
Brno 12
Des Moines 12
Kunming 12
Columbus 11
Verona 11
Manchester 10
Augusta 9
Baghdad 9
Belo Horizonte 9
Lahore 9
Modena 9
Querétaro 9
Taizhou 9
Totale 12.621
Nome #
Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors 289
Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth. 239
The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses. 235
Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection 224
Effects of defective herpes simplex vectors expressing neurotrophic factors on the proliferation and differentiation of nervous cells in vivo 221
CD40-signalling abrogates induction of RORγt+ Treg cells by intestinal CD103+ DCs and causes fatal colitis 221
Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer 218
An Attenuated Herpes Simplex Virus Type 1 (HSV1) Encoding the HIV-1 Tat Protein Protects Mice from a Deadly Mucosal HSV1 Challenge 216
Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. 209
Herpetic vectors inhibiting angiogenesis and inducing cell suicide in gliomas 201
Recombinant herpes simplex virus and uses therefor 200
A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease 197
HSV as a vector in vaccine development and gene therapy 181
null 179
HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy 178
Botulinum neurotoxin light chains expressed by defective herpes simplex virus type-1 vectors cleave snare proteins and inhibit cgrp release in rat sensory neurons 175
Herpesvirus-based vectors for gene transfer, gene therapy and the development of novel vaccines 167
HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma 166
Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity 166
Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients 163
Herpes Simplex Virus Growth, Preparation, and Assay 162
Development and application of replication-incompetent HSV-1-based vectors 160
Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus 160
Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice 159
HSV as a vector in vaccine development and gene therapy 159
Sustainable vs. Conventional Cleaning in Healthcare: Microbiological and Life Cycle Insights 159
Capitolo 55 Retrovirus 157
Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1 157
Temporal lobe epilepsy model, neural stem cells and gene therapy 155
Herpesvirus-based vaccines 154
Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes 154
The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells 153
Herpetic vectors inhibiting angiogenesis and Inducing cell suicide in gliomas 153
Herpes simplex virus type 1 infects enteric neurons and triggers gut dysfunction via macrophage recruitment 152
Role of Herpes Simplex Envelope Glycoprotein B and Toll-Like Receptor 2 in Ocular Inflammation: An ex vivo Organotypic Rabbit Corneal Model 151
Parenchymal cells critically curtail cytotoxic T-cell responses by inducing Bim-mediated apoptosis 149
Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo 147
Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8(+) T cell tolerance in vivo 146
Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice 145
Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity 144
Peripheral T Cells Re-Enter the Thymus and Interfere with Central Tolerance Induction 144
Purinergic Signaling: A New Pharmacological Target Against Viruses? 144
Control of Erwinia amylovora Growth by Moringa oleifera Leaf Extracts: In Vitro and in Planta Effects 144
Construction of Replication Defective Herpes Simplex Virus Vectors. 143
Gene transfer to muscle using herpes simplex virus-based vectors 141
Identification of replication-competent HSV-1 Cgal(+) strain targets in a mouse model of human hepatocarcinoma xenograft 141
MHC class I cross-presentation by dendritic cells counteracts viral immune evasion 140
Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines 139
Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region 139
Progress in development of herpes simplex virus gene vectors for treatment of rheumatoid arthritis 138
Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide 138
Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach 138
Herpes simplex virus type 1 (HSV-1)-derived recombinant vectors for gene transfer and gene therapy 138
Herpes simplex virus type 1 and Alzheimer’s disease: link and potential impact on treatment 138
Transcriptional targeting of B cells for induction of peripheral CD8 T cell tolerance 137
Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo 136
The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation 135
Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications 134
Engineering herpes simplex virus vectors for CNS applications 133
Development of Replication-Defective Herpes Simplex Virus Vectors 133
HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG35-55-induced experimental autoimmune encephalomyelitis in C57BL/6 mice 132
Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model 132
Ethosomal Gel for Topical Administration of Dimethyl Fumarate in the Treatment of HSV-1 Infections 131
Replication-deficient mutant Herpes Simplex Virus-1 targets professional antigen presenting cells and induces efficient CD4+ T helper responses 131
Connexin 43-enhanced suicide gene therapy using herpesviral vectors 130
Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects 130
Herpes Simplex Virus Type 1-Derived Recombinant and Amplicon Vectors 129
Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons 127
Effects of Moringa oleifera Leaf Extracts on Xanthomonas campestris pv. campestris 127
Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis 126
Advances in the development of herpes simplex virus-based gene transfer vectors for the nervous system 126
Capitolo 44 Herpesviridae 126
Viral Vector Expressing Tat As Immunomodulatory Molecule Represent A New Vaccine Strategy Against HSV Infection 126
Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type-1-derived vectors 124
High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type 1 vector 124
Cytokine gene delivery into the central nervous system using intrathecally injected nonreplicative viral vectors 123
Replication-defective herpes simplex virus vectors for gene transfer in vivo 123
An Evaluation of Hospital Cleaning Regimes—Microbiological Evaluation and LCA Analysis after Traditional and Sustainable/Green Procedures 121
Poster: Herpes simplex vaccine vector co-expressing fused Mycobacterium Tuberculosis immunogens and Tat adjuvant enhances cellular and humoral responses in Balb/c mice 121
A Safe-by-Design Approach for the Synthesis of a Novel Cross-Linked Hyaluronic Acid with Improved Biological and Physical Properties 120
Implications of maturation for viral gene delivery to skeletal muscle 120
Suppressing gain-of-function proteins via CRISPR/Cas9 system in SCA1 cells 119
Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant 117
Gene transfer to muscle and spinal cord using herpes simplex virus-based vectors. 116
Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors 116
Rapid method for construction of recombinant HSV gene transfer vectors 115
Comunicazione orale, Keynote speaker: Herpes Simplex Vector Expressing Hiv1 Tat: A New Strategy For Vaccine Development 112
Analysis of Civil Environments Cleaning Services—Microbiological and LCA Analysis after Traditional and Sustainable Procedures 111
Herpes Simplex Virus Growth, Preparation, and Assay 109
Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model 108
Strain specific maturation of Dendritic cells and production of IL-1β controls CD40-driven colitis 108
Hpv-specific systemic antibody responses and memory b cells are independently maintained up to 6 years and in a vaccine-specific manner following immunization with cervarix and gardasil in adolescent and young adult women in vaccination programs in Italy 108
Chapter 7 Gene Transfer to Muscle and Spinal Cord Using Herpes Simplex Virus-Based Vectors 107
Construction of replication-defective herpes simplex virus vectors. 107
Comunicazione orale, KN: A New Vaccine Approach To Fight Mycobacterium Tuberculosis 107
null 104
Chapter 8: Gene-transfer Tool: Herpes Simplex Virus Vectors 104
Herpes Simplex Virus ICP27 Protein Inhibits AIM 2-Dependent Inflammasome Influencing Pro-Inflammatory Cytokines Release in Human Pigment Epithelial Cells (hTert-RPE 1) 103
Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines 103
Engineering herpes simplex virus vectors for human gene therapy. 102
Totale 14.619
Categoria #
all - tutte 90.513
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 13.842
Totale 104.355


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.014 0 0 0 0 0 175 83 195 47 239 176 99
2021/20221.377 48 181 75 62 53 48 94 79 61 103 134 439
2022/20231.185 145 28 62 134 159 178 46 139 170 20 72 32
2023/2024882 80 84 42 26 38 260 55 43 20 25 22 187
2024/20252.856 82 79 232 111 382 314 46 172 379 329 419 311
2025/20265.060 952 344 811 1.165 1.251 537 0 0 0 0 0 0
Totale 18.518